Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.

Investigational new drugs - 1 Dec 2010

Santucci Maria Alessandra, Mancini Manuela, Corradi Valentina, Lacobucci Ilaria, Martinelli Giovanni, Botta Maurizio, Schenone Silvia

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Antineoplastic Agents
Share to Fusion Proteins, bcr-abl
Share to Lethal Dose 50

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Protein Kinase Inhibitors

Share to src-Family Kinases

Share to Tumor Stem Cell Assay

Source

Identifiers

PMID: 19629392
DOI: 10.1007/s10637-009-9294-9

Genes

SRC

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.PMID 19629392Read ↗

Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.Semantic proximity Read ↗

[Advancesin FLT3 inhibitors for acute myeloid leukemia].Semantic proximity Read ↗

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceSemantic proximity Read ↗

Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia.Semantic proximity Read ↗

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.Semantic proximity Read ↗

Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistanceSemantic proximity Read ↗

HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.Semantic proximity Read ↗

[Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with BCR-ABLT315I Mutation--Review].Semantic proximity Read ↗

HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.Semantic proximity Read ↗

Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.Semantic proximity Read ↗

[Pilot treatment for 13 BCR-ABL positive leukemia patients with T315I mutation].Semantic proximity Read ↗

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemiasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.